MedTrace Logo

Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers

NCT02829372 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-10-09

No results posted yet for this study

Summary

The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of GBR 1302 monotherapy in subjects with HER2 positive cancers

Conditions

  • HER2 Expressing Solid Tumours

Interventions

DRUG

CD3/HER2 bispecific monoclonal antibody

Increasing doses, IV on day 1 and 15 of each 28 day cycle

Sponsors & Collaborators

  • Glenmark Pharmaceuticals S.A.

    collaborator INDUSTRY

  • Ichnos Sciences SA

    lead INDUSTRY

Principal Investigators

  • Mikhail Khazan, MD · Ichnos Sciences SA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2019-05-31
Completion
2019-05-31
FDA Drug
Yes

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02829372 on ClinicalTrials.gov